← Back to Search
Immunohistochemical Profiles Of Brain Metastases From Breast Cancer
K. Yonemori, K. Tsuta, C. Shimizu, Y. Hatanaka, Kaoru Hashizume, M. Ono, Y. Nakanishi, T. Hasegawa, Y. Miyakita, Yoshitaka Narita, S. Shibui, Y. Fujiwara
Published 2008 · Medicine
Download PDFAnalyze on Scholarcy
The aim of present study is to explore the immunohistochemical profiles of brain metastases from breast cancer. We retrospectively performed immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor type 2 (HER2/neu), and cytokeratin (CK) 5/6 in 29 patients with resected tumor specimens of brain metastases. Immunohistochemical staining for ER, PgR and HER2/neu was performed in 24 patients with primary tumors. The positive frequency of immunohistochemical profiles of ER, PgR, HER2/neu, and CK5/6, in the brain metastases were 13.8%, 6.9%, 37.9%, and 24.1%, respectively. The immunohistochemical profiles including ER, PgR, and HER2/neu of the primary tumor and the brain metastasis differed in seven patients (29.2%, N = 7/24). Interestingly, the biological characteristics of brain metastasis sometimes changed which were represented by immunohistochemical staining. Therefore, the changes in the biological features of breast cancer should be taken into account when developing treatment strategies, including new molecular-targeted drugs, for brain metastases.
This paper references
c‐erbB‐2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues
C. Shimizu (2000)
HER-2/neu expression in primary and metastatic breast cancer
E. Lower (2008)
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
A. Clayton (2004)
Comparison of HER-2 Overexpression in Primary Breast Cancer and Metastatic Sites and Its Effect on Biological Targeting Therapy of Metastatic Disease
D. Hayes (2006)
Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
Y. Gong (2005)
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR
D. Hicks (2006)
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
R. Nahta (2006)
EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer.
S. Tsutsui (2002)
Trastuzumab in CSF.
B. Pestalozzi (2000)
CNS metastases in breast cancer.
N. Lin (2004)
Marked Intratumoral Heterogeneity of the Proto‐Oncogene Her‐2/neu Determined by Three Different Detection Systems
L. P. Pertschuk (1999)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
Y. Nagata (2004)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
Estrogen and progesterone receptor concordance between primary and recurrent breast cancer
Benjamin D. L. Li (1994)
Triple-negative breast cancer: therapeutic options.
S. Cleator (2007)
HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
D. Pectasides (2006)
understanding resistance to HER2-targeted therapy in human breast cancer
R Nahta (2008)
Incidence of central metastasis in patients treated with trastuzumab for metastatic breast cancer
AJ Clayton (2004)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers
S. Mohsin (2005)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
Primary breast cancer phenotypes associated with propensity for central nervous system metastases
K. Altundag (2006)
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.
D. Gancberg (2002)
Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence.
C. Kamby (1989)
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
J. Harvey (1999)
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.
A. Perren (1999)
The next step to approaching central nervous system metastasis in HER‐2‐positive metastatic breast cancer patients
K. Matsumoto (2006)
Change of HER‐2/neu status in a subset of distant metastases from breast carcinomas
P. Regitnig (2004)
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
J. Zidan (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
Her-2/neu status in breast cancer metastases to the central nervous system.
Kelly C. Lear-Kaul (2003)
Stability of HER-2/neu expression over time and at multiple metastatic sites.
G. Niehans (1993)
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
T. Nielsen (2004)
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.
F. Cardoso (2001)
This paper is referenced by
Relationship between estrogen receptor and brain tumors
L. Chang (2014)
Discordance of immunohistochemical markers between primary and recurrent or metastatic breast cancer
L. Peng (2020)
Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients
B. Rack (2011)
Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain.
Ajay D. Patil (2015)
Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer
C. Bachmann (2013)
Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases.
Y. Okita (2013)
Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
J. Jung (2017)
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.
R. Duchnowska (2015)
Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm
I. Meattini (2020)
CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary
C. Bachmann (2012)
Relationship between estrogen receptor and brain tumors
L. Chan (2014)
A subset of breast cancer predisposes to brain metastasis
M. Shao (2010)
Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
K. Arihiro (2013)
Subtype switching in breast cancer brain metastases: a multicenter analysis
A. Hulsbergen (2020)
Clinical analysis of patients with central nervous system metastases from breast cancer
L. Gottwald (2012)
Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients
B. Rack (2016)
Breast Cancers with Brain Metastases
Maribel D. Lacambra (2015)
Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.
W. Schrijver (2017)
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain
R. Duchnowska (2012)
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
H. Kurihara (2015)
Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review
C. Yeung (2016)
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
W. Schrijver (2018)
Estrogen, Progesterone and HER2 Receptor Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival.
P. Sperduto (2020)
First-line BP Therapy Effected a Radical Improvement of the Brain Metastasis in a Breast Cancer Patient
Toshiro Shimo (2017)
Survival among women with triple receptor-negative breast cancer and brain metastases.
S. Dawood (2009)
Mammaglobin-A Immunohistochemistry in Primary Central Nervous System Neoplasms and Intracranial Metastatic Breast Carcinoma
P. J. Cimino (2014)
Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study
O. Kaidar-Person (2017)
Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes
A. Thomson (2016)